ATE458751T1 - Kombinationschemotherapie mit chlorotoxin - Google Patents

Kombinationschemotherapie mit chlorotoxin

Info

Publication number: ATE458751T1
Authority: AT; Austria
Prior art keywords: chlorotoxin; combination chemotherapy; combination; derivative; chemotherapy
Prior art date: 2002-05-31

Application number

AT03731504T

Other languages

English (en)

Inventor

Vermont L Alvarez

Carol A Grimes

Matthew A Gonda

Original Assignee

Transmolecular Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-31

Filing date

2003-06-02

Publication date

2010-03-15

2003-06-02 Application filed by Transmolecular Inc filed Critical Transmolecular Inc

2010-03-15 Application granted granted Critical

2010-03-15 Publication of ATE458751T1 publication Critical patent/ATE458751T1/de

Links

101710164760 Chlorotoxin Proteins 0.000 title abstract 2
QPAKKWCQMHUHNI-GQIQPHNSSA-N chlorotoxin Chemical compound C([C@H]1C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]4CSSC[C@@H](C(N[C@@H](CCSC)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)CNC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC2=O)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC4=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N3)=O)NC(=O)[C@@H](N)CCSC)C1=CC=C(O)C=C1 QPAKKWCQMHUHNI-GQIQPHNSSA-N 0.000 title abstract 2
229960005534 chlorotoxin Drugs 0.000 title abstract 2
238000009096 combination chemotherapy Methods 0.000 title 1
239000002246 antineoplastic agent Substances 0.000 abstract 1
238000002648 combination therapy Methods 0.000 abstract 1
229940127089 cytotoxic agent Drugs 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Insects & Arthropods (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Tropical Medicine & Parasitology (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

AT03731504T 2002-05-31 2003-06-02 Kombinationschemotherapie mit chlorotoxin ATE458751T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US38417102P	2002-05-31	2002-05-31
US40603302P	2002-08-27	2002-08-27
PCT/US2003/017410 WO2003101474A1 (en)	2002-05-31	2003-06-02	Combination chemotherapy with chlorotoxin

Publications (1)

Publication Number	Publication Date
ATE458751T1 true ATE458751T1 (de)	2010-03-15

Family

ID=29715313

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03731504T ATE458751T1 (de)	2002-05-31	2003-06-02	Kombinationschemotherapie mit chlorotoxin

Country Status (10)

Country	Link
US (1)	US20060166892A1 (de)
EP (4)	EP1553962B1 (de)
JP (3)	JP2005537234A (de)
AT (1)	ATE458751T1 (de)
AU (2)	AU2003237347B2 (de)
CA (2)	CA2487425A1 (de)
DE (1)	DE60331458D1 (de)
ES (1)	ES2341767T3 (de)
MX (1)	MXPA04011871A (de)
WO (2)	WO2003101475A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060088899A1 (en) *	2002-05-31	2006-04-27	Alvarez Vernon L	Combination chemotherapy with chlorotoxin
US20070275902A1 (en) *	2003-11-26	2007-11-29	Transmolecular, Inc.	Treatment of Phosphatidylinositol Phospholipid Disorders
ATE459642T1 (de) *	2004-04-06	2010-03-15	Transmolecular Inc	Diagnose und behandlung von myeloid- und lymphoidzellenkrebs mit chlorotoxin oder derivat
EP1877428B1 (de) *	2005-04-22	2011-03-16	University of Washington	Fluoreszentes chlorotoxinkonjugat und verfahren zur intraoperativen sichtbarmachung von krebs
CA2647907A1 (en) *	2006-03-31	2007-10-18	Transmolecular, Inc.	Use of tm-601 for the diagnosis and treatment of tumors
US8106013B2 (en)	2006-05-19	2012-01-31	Georgia Tech Research Corporation	ABC transporter ligand GATX1
CN100590130C (zh) *	2007-07-31	2010-02-17	厦门北大之路生物工程有限公司	抗癌活性肽
EP2173385A1 (de) *	2007-08-07	2010-04-14	Transmolecular, Inc.	Chlorotoxine als wirkstoffträger
CA2702314A1 (en) *	2007-10-12	2009-04-16	Transmolecular, Inc.	Systemic administration of chlorotoxin agents for the diagnosis and treatment of tumors
CN102438646A (zh) *	2008-05-15	2012-05-02	特兰斯莫莱库拉公司	转移性肿瘤的治疗
CA2724384A1 (en)	2008-05-15	2009-11-19	Transmolecular, Inc.	Treatment of metastatic tumors
WO2010086964A1 (ja) *	2009-01-28	2010-08-05	株式会社静岡カフェイン工業所	がん治療のための併用療法
JP5858932B2 (ja) *	2010-02-04	2016-02-10	モルフォテック，インコーポレイテッド	クロロトキシンポリペプチドおよびコンジュゲートならびにその使用
ES2601182T3 (es) *	2010-05-11	2017-02-14	Fred Hutchinson Cancer Research Center	Variantes de clorotoxina, conjugados y métodos para su utilización
CU24055B1 (es) *	2010-09-27	2014-12-26	Grupo Empresarial De Producciones Biofarmacéuticas Y Químicas Labiofam	Composiciones farmacéuticas de veneno de escorpión rhopalurus junceus
GB201106004D0 (en)	2011-04-08	2011-05-25	Univ Edinburgh	Optical imaging probes
WO2013003507A1 (en)	2011-06-27	2013-01-03	Morphotek, Inc.	Multifunctional agents
WO2013158803A1 (en)	2012-04-17	2013-10-24	Merrimack Pharmaceuticals, Inc.	Compositions and methods for non-invasive imaging
AU2013202947B2 (en)	2012-06-13	2016-06-02	Ipsen Biopharm Ltd.	Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en)	2012-06-13	2017-08-01	Ipsen Biopharm Ltd.	Methods for treating pancreatic cancer using combination therapies
SG11201504600UA (en)	2012-12-10	2015-07-30	Hutchinson Fred Cancer Res	Methods for screening
JP2016523818A (ja) *	2013-04-18	2016-08-12	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	それを必要とする被験体におけるｔ細胞増殖を阻害するための方法及び医薬組成物（ｃｔｐｓ１阻害剤、例えばノルロイシン）
US11559580B1 (en)	2013-09-17	2023-01-24	Blaze Bioscience, Inc.	Tissue-homing peptide conjugates and methods of use thereof
WO2015061592A1 (en) *	2013-10-23	2015-04-30	Merrimack Pharmaceuticals, Inc.	Liposomes for non-invasive imaging and drug delivery
US9522114B1 (en) *	2014-03-27	2016-12-20	University Of South Florida	Enhanced targeted drug delivery system via chitosan hydrogel and chlorotoxin
US11318131B2 (en)	2015-05-18	2022-05-03	Ipsen Biopharm Ltd.	Nanoliposomal irinotecan for use in treating small cell lung cancer
SG10201913073YA (en)	2015-08-20	2020-03-30	Ipsen Biopharm Ltd	Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
EP3791876A1 (de)	2015-08-21	2021-03-17	Ipsen Biopharm Ltd.	Verfahren zur behandlung von metastasierendem bauchspeicheldrüsenkrebs mithilfe von kombinationstherapien mt liposomalem irinotecan und oxaliplatin
CA3053242A1 (en) *	2016-02-19	2017-08-24	Dignity Health	Antibody fusion protein and related compositions for targeting cancer
US12048732B2 (en)	2016-04-15	2024-07-30	Blaze Bioscience, Inc.	Methods of treating breast cancer
KR101678393B1 (ko)	2016-08-25	2016-12-06	(주)넥스젠바이오텍	피부 세포 증식 효과가 증가한 전갈독 융합단백질 및 이를 유효성분으로 함유하는 피부 주름 개선, 피부 탄력 증대 및 항노화 화장료 조성물
RU2761953C2 (ru)	2016-11-02	2021-12-14	Ипсен Биофарм Лтд.	Лечение рака желудка с применением комбинационных видов терапии, содержащих липосомальный иринотекан, оксалиплатин, 5-фторурацил (и лейковорин)
WO2019055840A1 (en)	2017-09-15	2019-03-21	Eisai Inc.	CHLOROTOXIN AGENTS AND USES THEREOF
JP7386161B2 (ja) *	2017-12-19	2023-11-24	ブレイズバイオサイエンス，インコーポレイテッド	腫瘍ホーミング及び細胞透過性ペプチド免疫抗がん剤複合体、ならびにそれらの使用方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69025946T2 (de) *	1989-09-08	1996-10-17	Univ Duke	Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
US5223253A (en) *	1989-09-28	1993-06-29	American Home Products Corporation	Bovine vaccine compositions and method for preventing trichomonas infections using same
US5750376A (en) *	1991-07-08	1998-05-12	Neurospheres Holdings Ltd.	In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
IL108328A (en) *	1993-01-14	2010-05-31	Cancer Res Campaign Tech	Pharmaceutical compositions containing temozolomide and atase inhibitor for potentiation of temozolomide toxicity to human tumor cells
US5626862A (en) *	1994-08-02	1997-05-06	Massachusetts Institute Of Technology	Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5756340A (en) *	1995-05-08	1998-05-26	The Regents Of The University Of California	Insect control with multiple toxins
JP3809502B2 (ja) *	1995-05-30	2006-08-16	二郎有川	ハンタウィルス抗原蛋白質およびモノクローナル抗体
JPH0971599A (ja) *	1995-09-06	1997-03-18	Nippon Seibutsu Kagaku Kenkyusho	鶏貧血ウイルス（ｃａｖ）感染鶏血清と高い反応性を示すポリペプチド及びこのポリペプチドに対する抗体、鶏貧血ウイルス感染の診断法及びワクチン
US5905027A (en) *	1995-12-27	1999-05-18	Uab Research Foundation	Method of diagnosing and treating gliomas
US6667156B2 (en) *	1995-12-27	2003-12-23	Uab Research Foundation	Diagnosis and treatment of neuroectodermal tumors
EP1055684A4 (de) *	1997-12-05	2002-12-04	Kyogo Itoh	Tumorantigene in form von peptidderivaten

2003
- 2003-06-02 CA CA002487425A patent/CA2487425A1/en not_active Abandoned
- 2003-06-02 EP EP03731504A patent/EP1553962B1/de not_active Expired - Lifetime
- 2003-06-02 ES ES03731504T patent/ES2341767T3/es not_active Expired - Lifetime
- 2003-06-02 AU AU2003237347A patent/AU2003237347B2/en not_active Ceased
- 2003-06-02 US US10/522,810 patent/US20060166892A1/en not_active Abandoned
- 2003-06-02 WO PCT/US2003/017411 patent/WO2003101475A1/en not_active Ceased
- 2003-06-02 EP EP03736810A patent/EP1539207A4/de not_active Withdrawn
- 2003-06-02 DE DE60331458T patent/DE60331458D1/de not_active Expired - Lifetime
- 2003-06-02 JP JP2004508829A patent/JP2005537234A/ja active Pending
- 2003-06-02 EP EP10178613A patent/EP2431385A3/de not_active Withdrawn
- 2003-06-02 AU AU2003240496A patent/AU2003240496B2/en not_active Expired
- 2003-06-02 CA CA002494451A patent/CA2494451A1/en not_active Abandoned
- 2003-06-02 AT AT03731504T patent/ATE458751T1/de not_active IP Right Cessation
- 2003-06-02 WO PCT/US2003/017410 patent/WO2003101474A1/en not_active Ceased
- 2003-06-02 EP EP09176234A patent/EP2182004A1/de not_active Withdrawn
- 2003-06-02 MX MXPA04011871A patent/MXPA04011871A/es active IP Right Grant
2011
- 2011-03-09 JP JP2011052039A patent/JP5856744B2/ja not_active Expired - Lifetime
2015
- 2015-07-03 JP JP2015134259A patent/JP2015214562A/ja active Pending

Also Published As

Publication number	Publication date
EP2431385A3 (de)	2012-07-04
DE60331458D1 (de)	2010-04-08
AU2003237347A1 (en)	2003-12-19
EP1539207A1 (de)	2005-06-15
CA2487425A1 (en)	2003-12-11
JP2011153149A (ja)	2011-08-11
CA2494451A1 (en)	2003-12-11
US20060166892A1 (en)	2006-07-27
EP2431385A2 (de)	2012-03-21
EP1539207A4 (de)	2008-01-02
EP2182004A1 (de)	2010-05-05
JP5856744B2 (ja)	2016-02-10
JP2015214562A (ja)	2015-12-03
AU2003240496A1 (en)	2003-12-19
AU2003237347B2 (en)	2009-07-23
WO2003101475A1 (en)	2003-12-11
JP2005537234A (ja)	2005-12-08
WO2003101474A1 (en)	2003-12-11
MXPA04011871A (es)	2005-07-26
ES2341767T3 (es)	2010-06-28
EP1553962A1 (de)	2005-07-20
AU2003240496B2 (en)	2008-01-10
EP1553962B1 (de)	2010-02-24
EP1553962A4 (de)	2008-01-02

Legal Events

Date	Code	Title	Description
2010-08-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60331458D1 (de)	2010-04-08	Kombinationschemotherapie mit chlorotoxin
ATE407967T1 (de)	2008-09-15	Nukleierungsmittel
CY1112687T1 (el)	2016-02-10	Μεθοδος για χρηση δικετοπιπεραζινων και συνθεσεις που περιλαμβανουν αυτες
NO20073135L (no)	2007-12-27	Nedihulls-verktoy betjent av lineaer induksjonsmotor
DE602005010109D1 (de)	2008-11-13	1,1a,5,5a-tetrahydro-3-thia-cyclopropaäaüpentaleneptor-agonisten
NL1023157A1 (nl)	2003-10-14	Stabilisatormengsels.
DK1847611T3 (da)	2010-01-04	Rhamnose-inducerbart ekspressionssystem
TR200202194T2 (tr)	2003-01-21	Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri
DK1718677T3 (da)	2012-07-09	Monovalente antistoffragmenter egnede som terapeutiske midler
NO20052993D0 (no)	2005-06-17	4,5-diaryltiazolderivater som CB-1 ligander.
EP1555267A4 (de)	2010-08-18	2,3-DIHYDRO-6-NITROIMIDAZOç2,1-b]OXAZOLE
HRP20070374T3 (en)	2007-10-31	Formulations comprising ecteinascidin and a disaccharide
DK1265911T3 (da)	2008-09-29	17-alfa-substitueret-11-beta-substitueret-4-aryl og 21-substitueret 19-norpregnadiendion som antiprogestationelle midler
SE0301650D0 (sv)	2003-06-04	Novel compounds
MY135452A (en)	2008-04-30	2-methyl-thieno-benzodiazepine lyophilized formulation
ATE452646T1 (de)	2010-01-15	Zusammensetzungen mit epigallocatechingallat und proteinhydrolysat
ITTO20020157A0 (it)	2002-02-25	Macchina depallettizzatrice.
NO20064762L (no)	2007-04-23	Heisdorsystem
BRPI0500536A (pt)	2005-12-06	Composição antimicrobiana
ITMO20050005U1 (it)	2006-09-21	Mola da taglio perfezionata
ITTO20020744A1 (it)	2003-02-25	Composizione.
BRPI0410638A (pt)	2006-06-13	derivados de azitromicina
BR0111842A (pt)	2004-03-02	Solução concentrada à base de poliamida, processos de fabricação e composições
TW200724152A (en)	2007-07-01	Oligopeptide, derivative thereof, and pharmaceutical composition comprising the same
ITTO20020745A1 (it)	2003-02-25	Composizione.